Most prominently, inhibition of increased TGF-β signaling in a cohort of low-risk MDS patients using recombinant luspatercept showed beneficial effects on MDS-related anemia and reduced transfusion-dependency in a recent phase 3 trial [69]. Here, TGFB1 is linked to myelodysplastic syndrome.